预测活性炎症性肠病 (PRIme) 患者对补充铁的反应:一个随机试验协议
Roberta Loveikyte1,2, Marjolijn Duijvestein3, Zlatan Mujagic4
1Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands r.loveikyte@lumc.nl.
BMJ open
|January 31, 2024
概括
这项研究调查了肝素水平是否可以预测炎症性肠病 (IBD) 患者的治疗反应,这些患者患有缺铁性贫血 (IDA). 了解肝素可以指导最佳的铁补充策略,以改善患者的治疗结果.
科学领域:
- 胃肠病学 胃肠病学
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 缺铁性贫血 (IDA) 是炎症性肠病 (IBD) 的常见并发症,影响患者的生活质量和疾病预后.
- 由于其复杂的原因和频繁的复发,IBD中的铁缺乏症 (ID) 存在诊断和治疗方面的挑战.
- 铁调节剂肝素的升高与IBD的口服铁吸收不良有关,这表明它在治疗选择中的潜在作用.
研究的目的:
- 评估肝素作为铁治疗反应的预测生物标志物在活跃IBD患者的实用性.
- 为了比较口服铁酸盐,口服铁和静脉注射铁在治疗IBD中的有效性.
- 评估铁补充剂对IBD患者生活质量和疾病负担的影响.
主要方法:
- PRIme试验是一个多中心的,开放的,随机的研究,涉及90名成年IBD患者ID(A).
- 参与者被随机分为三个组:口服铁,口服铁或静脉注射铁.
- 肝素水平,铁状况生物标志物和患者报告的结果在基线和6,14和24周时收集.
主要成果:
- 主要结局是肝素对铁疗法反应的预测值,通过接收器操作曲线分析进行分析.
- 将分析生化和临床数据,以确定治疗疗效和肝素的预测能力.
- 患者报告的结果将评估不同铁疗法对生活质量的影响.
结论:
- 肝素可以作为一个有价值的生物标志物,指导IBD患者选择适当的铁补充剂.
- 这项研究旨在优化铁管理策略,潜在地改善IBD治疗结果和患者福祉.
- 这些发现将有助于个性化医疗方法来管理慢性炎症病的铁缺乏症.
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
334
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
334
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
166
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
166
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
120
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
120
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137
Inflammatory Bowel Disease II: Crohn's Disease
244
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
244


